Aemetis (NASDAQ:AMTX) Coverage Initiated by Analysts at Piper Sandler

Piper Sandler started coverage on shares of Aemetis (NASDAQ:AMTX – Get Rating) in a research report report published on Monday, The Fly reports. The brokerage issued an underweight rating on the specialty chemicals company’s stock.

AMTX has been the topic of several other research reports. UBS Group assumed coverage on Aemetis in a research note on Tuesday, December 13th. They set a neutral rating and a $4.25 target price on the stock. Ascendiant Capital Markets decreased their target price on shares of Aemetis to $26.00 in a research report on Wednesday, November 16th. Finally, Truist Financial decreased their price objective on Aemetis from $9.00 to $5.00 and set a hold rating on the stock in a research report on Wednesday, February 1st. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Aemetis presently has a consensus rating of Hold and an average target price of $15.56.

Aemetis Price Performance

Shares of AMTX stock opened at $3.85 on Monday. The company has a market cap of $134.90 million, a price-to-earnings ratio of -1.49 and a beta of 0.87. Aemetis has a 1 year low of $3.62 and a 1 year high of $16.06. The firm has a fifty day moving average price of $4.18 and a 200-day moving average price of $5.95.

Institutional Trading of Aemetis

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Barclays PLC grew its position in Aemetis by 542.0% during the 4th quarter. Barclays PLC now owns 8,031 shares of the specialty chemicals company’s stock worth $32,000 after purchasing an additional 6,780 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Aemetis by 173.7% in the third quarter. Tower Research Capital LLC TRC now owns 5,586 shares of the specialty chemicals company’s stock valued at $34,000 after acquiring an additional 3,545 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in Aemetis by 105.6% during the second quarter. BNP Paribas Arbitrage SA now owns 9,517 shares of the specialty chemicals company’s stock worth $47,000 after buying an additional 4,887 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Aemetis in the fourth quarter worth about $49,000. Finally, SG Americas Securities LLC purchased a new position in Aemetis during the second quarter worth approximately $54,000. Hedge funds and other institutional investors own 50.72% of the company’s stock.

Aemetis Company Profile

(Get Rating)

Aemetis, Inc is a renewable fuels and biochemical company, which engages in the acquisition, development, and commercialization of technologies that replace traditional petroleum-based products. It operates through the North America and India geographical segments. The North America segment manages Keyes Plant in California, the cellulosic ethanol facility in Riverbank, the cluster of biogas digesters on dairies near Keyes, California, the Goodland Plant, Kansas and the research and development facility in Minnesota.